Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: Harold Engstrom who wrote (3159)	8/30/2002 8:29:49 AM
From: Icebrg	Read Replies (3) \| Respond to of 10345

Harold, You are right that there might be some sales left in the product if Elan will pursue further sales of Naprelan. But I don't believe that Elan will put any efforts into selling this product any more against generic competition. Especially as the sales volume even before the approval was less than what Elan has said was of interest to them. They have been busy out-licensing drugs with low sales volumes over the last year and a half. Now, there will most probably not be much left to milk from this particular cow. The approval doesn't seem to have come completely unexpected, as Elan took a write-down in the second quarter on IP related to Naprelan. Ice